• Profile
Close

Effect of costimulatory blockade with abatacept in plaque psoriasis

JAMA Oct 20, 2021

Harris KM, Smilek DE, Byron M, et al. - Findings revealed failure of abatacept in preventing psoriasis relapse that occurred after ustekinumab withdrawal. This inability to prevent relapse was due to failure to completely block the pathogenic psoriasis molecular pathways that resulted in relapse.

  • This is a parallel-design, double-blind randomized clinical trial of 91 adults with moderate to severe plaque psoriasis who were randomized to the abatacept group or to the ustekinumab group.

  • Relapse between weeks 12 and 88 occurred in similar proportions of participants in the abatacept group and the ustekinumab group (91.1% vs 87.0%).

  • The median time to relapse from the last dose of ustekinumab was found to be similar between groups (36 weeks in the abatacept group vs 32 weeks in the ustekinumab group).

  • The numbers and rates of adverse events were also similar between the groups.

  • Abatacept failed to maintain suppression of the pathogenic interkeukin (IL)-23-mediated psoriasis molecular signature in lesions following withdrawal of ustekinumab, and serum IL-19 levels raised.

Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
x
M3 app logo
Choose easy access to M3 India from your mobile!


M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen
Okay